Search

Your search keyword '"Greillier, L"' showing total 129 results
Start Over Author "Greillier, L" Search Limiters Peer Reviewed
129 results on '"Greillier, L"'

2. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Author

Remon, J., Besse, B., Aix, S. Ponce, Callejo, A., Al-Rabi, K., Bernabe, R., Greillier, L., Majem, M., Reguart, N., Monnet, I., Cousin, S., Garrido, P., Robinet, G., Garcia Campelo, R., Madroszyk, A., Mazières, J., Curcio, H., Wasąg, B., Pretzenbacher, Y., Fournier, B., Dingemans, A.-M.C., and Dziadziuszko, R.

Published
2023
Full Text
View/download PDF

5. The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer

Author

Mogenet A, Greillier L, and Tomasini P

Subjects
molecular biology – targeted therapy – lung cancer – immunotherapy – biomarkers, Therapeutics. Pharmacology, RM1-950
Abstract

Alice Mogenet, Laurent Greillier, Pascale Tomasini Aix Marseille University, CNRS, INSERM, CRCM, APHM, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, FranceCorrespondence: Pascale TomasiniService d’Oncologie Multidisciplinaire et Innovations Thérapeutiques, Hôpital Nord, Chemin des Bourrely, Marseille Cedex, 13915, FranceTel +33 4 91 96 59 01Fax +33 4 91 96 59 02Email pascale.tomasini@ap-hm.frAbstract: During the past decade, progress has been made in the field of lung cancer molecular biology and onco-immunology, leading to prolonged survival of patients. The combination of increased fundamental knowledge and the pharmaceutical pipeline has allowed the development of various tyrosine kinase inhibitors, targeting numerous molecular alterations. These drugs are now available in daily practice and have transformed survival outcomes for patients harboring EGFR, ALK or ROS1 alterations. Multiple clinical trials are now ongoing in order to increase the number of approved drugs, thus overcoming the issues of rare mutations and tyrosine kinase inhibitors resistance. Immune checkpoint inhibitors development has also changed lung cancer outcomes, but underwhelming response rates highlight the need for immune biomarkers. While PD-L1 expression was the first approved immune biomarker, it has shown several limitations and new biomarkers have to be identified to predict response or resistance to immune checkpoint inhibitors. Testing methods, molecular results and targeted therapeutic schedules will be harmonized in the coming years, with the help of dedicated molecular multidisciplinary boards.Keywords: molecular biology, targeted therapy, lung cancer, immunotherapy, biomarkers

Published
2021

10. Medication Reconciliation Associated with Comprehensive Geriatric Assessment in Older Patients with Cancer: ChimioAge Study

Author

Couderc AL, Boisseranc C, Rey D, Nouguerede E, Greillier L, Barlesi F, Duffaud F, Deville L, Honoré S, Villani P, and Correard F

Subjects
aged, antineoplastic protocols, geriatric assessment, medication reconciliation, treatment failure, Geriatrics, RC952-954.6
Abstract

Anne-Laure Couderc,1,2 Celia Boisseranc,3 Dominique Rey,1 Emilie Nouguerede,1 Laurent Greillier,4,5 Fabrice Barlesi,4,5 Florence Duffaud,4,6 Jean-Laurent Deville,6 Stéphane Honoré,3,4 Patrick Villani,1,2 Florian Correard3,4 1Internal Medicine, Geriatry and Therapeutic Unit, AP-HM, Marseille, France;Coordination Unit for Geriatric Oncology (UCOG), PACA West, Marseille, France; 2Aix-Marseille Université, CNRS, EFS, ADES, Marseille, France; 3Pharmacology Department, AP-HM, Marseille, France; 4Aix-Marseille University, Marseille, France; 5Multidisciplinary Oncology and Therapeutic Innovations Unit, AP-HM, Marseille, France; 6Oncology Unit, AP-HM, Marseille, FranceCorrespondence: Anne-Laure CoudercCoordination Unit for Geriatric Oncology (UCOG), PACA West, University Hospital of Marseille (AP-HM), 270 Boulevard De Sainte Marguerite, Marseille 13009, FranceTel +33 491744530Fax +33 491744833Email anne-laure.couderc@ap-hm.frBackground: Polymorbidity induces polypharmacy in older patients may lead to potential drug–drug interactions (DDI) which can modify the tolerance and safety of oncological treatments and alter the intended therapeutic effect. The objective of our study was to describe the decision-making process for oncological treatment and related outcomes, in a population of older adults undergoing a comprehensive geriatric assessment (CGA) associated to a comprehensive medication reconciliation (CMR) prior to initiating oncological treatment.Methods: ChimioAge is a prospective observational study conducted between 01/2017 and 07/2018 at Marseille University Hospital and approved by the French National Ethics Committee. It comprised all consecutive patients aged 70 years and over who were referred for a CGA as part of CMR, before initiating systemic treatment.Results: One hundred and seventy-one cancer patients were included. Mean age was 79.2 years, over half had metastatic cancers, 75% had an ECOG performance status zero or one, and two-thirds were independent in daily activities. Two-thirds of the patients had polypharmacy and the CMR identified potential DDI with systemic treatment in 43.3% of patients. Following the CGA, the CMR and the hospital oncologists decision, 30% of the patients received adapted systemic treatment with reduced doses at initiation. They presented fewer toxicities – irrespective of grade and type – than patients who received standard treatment (p< 0.001) and had comparable overall survival (Log rank p=0.21).Conclusion: This is one of the first studies to highlight the value in conducting CMR and a CGA simultaneously before initiating systemic treatment in older patients with cancer. These two evaluations could give oncologists decisive information to personalize cancer treatment of older patients and optimize treatment dose to offer the best efficacy and minimize toxicity.Keywords: aged, antineoplastic protocols, geriatric assessment, medication reconciliation, treatment failure

Published
2020

25. Le dépistage individuel du cancer broncho-pulmonaire en pratique. Perspectives sur les propositions du groupe de travail pluridisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Groupe d’oncologie de langue française

Author

Girard, N., Gounant, V., Mennecier, B., Greillier, L., Cortot, A.B., Couraud, S., Besse, B., Brouchet, L., Castelnau, O., Ferretti, G.R., Frappé, P., Khalil, A., Lefebure, P., Laurent, F., Liebart, S., Margery, J., Molinier, O., Quoix, E., Revel, M.-P., Stach, B., Souquet, P.-J., Thomas, P., Trédaniel, J., Lemarié, E., Zalcman, G., Barlési, F., and Milleron, B.

Published
2014
Full Text
View/download PDF

27. From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)

Author

Couraud, S., Cortot, A.B., Greillier, L., Gounant, V., Mennecier, B., Girard, N., Besse, B., Brouchet, L., Castelnau, O., Frappé, P., Ferretti, G.R., Guittet, L., Khalil, A., Lefebure, P., Laurent, F., Liebart, S., Molinier, O., Quoix, E., Revel, M.-P., Stach, B., Souquet, P.-J., Thomas, P., Trédaniel, J., Lemarié, E., Zalcman, G., Barlési, F., and Milleron, B.

Published
2013
Full Text
View/download PDF

31. 1260P Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study.

Author

Doucet, L., Greillier, L., Planchard, D., Mazieres, J., Felip, E., Bosch-Barrera, J., Cobo Dols, M., Ghiringhelli, F., Bearz, A., Paz-Ares, L.G., Tiseo, M., Carcereny, E., Zalcman, G., Di Noia, V.P., de Castro Carpeño, J., Soto Parra, H.J., Corral Jaime, J., Zheng, L., Yang, J.C-H., and Jänne, P.A.

Subjects
*INSERTION mutation, *EPIDERMAL growth factor receptors, *PLATINUM, *NON-small-cell lung carcinoma
Published
2024
Full Text
View/download PDF

48. 1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial.

Author

Gounant, V., Greillier, L., Mascaux, C., Pinquie, F., Carmier, D., Moreau, L., Roch, B., Debieuvre, D., Dhalluin, X., Giroux-Leprieur, E., Berton, E., Rabeau, A., Raimbourg, J., Dixmier, A., Naltet, C., Khalil, A., Ezzeddine, L., Langlais, A., Morin, F., and Duruisseaux, M.

Subjects
*NON-small-cell lung carcinoma, *PROGRAMMED death-ligand 1, *TUMORS
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results